MDxHealth SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
Provider : Sadif Analytics Prime
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
MDxHealth's ConfirmMDx Genes identify aggressive prostate cancer
MDxHealth SA:Announces positive results from an important study of its ConfirmMDx for Prostate Cancer genes designed to identify patients with aggressive prostate cancer (PCa).Says the study confirmed that epigenetic profiling of selected genes provides prognostic information, corresponding to Gleason score (GS), that could help to identify patients with aggressive PCa.Says within the study the prognostic value of the epigenetic status of five genes (GSTP1, APC, RASSF1, RARB and LGALS3) in 84 prostatectomy samples with different GS's was evaluated.Says the results of a hierarchical clustering analysis showed that low gene methylation levels were detected in the vast majority of patient samples with GS6 and GS7 (3+4) PCa.Says in contrast, respectively 81 percent and 91 percent of the GS7 (4+3) and GS superior or equal eight samples fell into the category with intermediate to high methylation levels.Says these data provide evidence of the potential prognostic value of epigenetically profiling selected genes to identify men with a low versus high risk for aggressive PCa.
Latest Key Developments inBiotechnology
- Motif Bio plc says FDA Grants Fast Track Designation for Iclaprim
- TESARO Inc Announces U.S. FDA Approval of VARUBI (rolapitant) for Nausea and Vomiting Associated With Cancer Chemotherapy
- Flexion Therapeutics granted fast track status by the FDA for FX006
- Neurovive Pharmaceutical says Jan Nilsson new interim CEO
- Share this
- Digg this